TCM
BPMC

Tekla Capital Management’s Blueprint Medicines BPMC Stock Holding History

Tekla Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-67,710
Closed -$3.05M – 172
2023
Q1 		$3.05M Hold
67,710
– – 0.12% 98
2022
Q4 		$2.97M Buy
+67,710
New +$3.25M 0.11% 102
2022
Q3 		– Sell
-111,118
Closed -$5.61M – 172
2022
Q2 		$5.61M Buy
111,118
+13,865
+14% +$812K 0.22% 84
2022
Q1 		$6.21M Buy
+97,253
New +$6.98M 0.22% 86
2021
Q3 		– Sell
-122,699
Closed -$10.8M – 177
2021
Q2 		$10.8M Hold
122,699
– – 0.35% 78
2021
Q1 		$11.9M Hold
122,699
– – 0.41% 63
2020
Q4 		$13.8M Sell
122,699
-47,319
-28% -$4.99M 0.48% 58
2020
Q3 		$15.8M Buy
170,018
+51,762
+44% +$3.99M 0.59% 43
2020
Q2 		$9.22M Sell
118,256
-21,080
-15% -$1.43M 0.35% 59
2020
Q1 		$8.15M Buy
139,336
+22,411
+19% +$1.44M 0.37% 51
2019
Q4 		$9.37M Buy
116,925
+16,009
+16% +$1.2M 0.35% 65
2019
Q3 		$7.41M Buy
100,916
+5,940
+6% +$513K 0.32% 64
2019
Q2 		$8.96M Sell
94,976
-20,744
-18% -$1.71M 0.37% 62
2019
Q1 		$9.26M Sell
115,720
-9,487
-8% -$701K 0.38% 57
2018
Q4 		$6.75M Sell
125,207
-20,794
-14% -$1.26M 0.29% 68
2018
Q3 		$11.4M Hold
146,001
– – 0.41% 55
2018
Q2 		$9.27M Buy
146,001
+71,780
+97% +$5.71M 0.35% 65
2018
Q1 		$6.81M Buy
+74,221
New +$6.4M 0.26% 82

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tekla Capital Management's BPMC Position: Q2 2023 in Review

Tekla Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2023, closing a stake of 67,710 shares — an estimated $3.05M sold.

Tekla Capital Management first reported a position in BPMC in Q1 2018 and held it in 18 quarters. The position peaked at $15.8M in Q3 2020. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

  • Tekla Capital Management reported no remaining Blueprint Medicines position as of Q2 2023 after selling out during the quarter.
  • Tekla Capital Management sold 67,710 Blueprint Medicines shares in Q2 2023, an estimated $3.05M.
  • Tekla Capital Management first reported a position in Blueprint Medicines in Q1 2018 and held it in 18 quarters.
  • Tekla Capital Management's Blueprint Medicines position peaked at $15.8M in Q3 2020.
  • 222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.